STEMCENTRX ACQUISITION

April 28, 2016
Forward-Looking Statements and Non-GAAP Financial Information

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2015 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

This presentation contains GAAP and certain non-GAAP financial measures. Non-GAAP financial measures are adjusted for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in AbbVie’s reconciliation tables. AbbVie’s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie’s results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s Web site at www.abbvieinvestor.com.
Stemcentrx: A Strategically Compelling Acquisition

Creating a highly attractive foundational platform for solid tumors, utilizing cancer stem cell biology

Lead asset, Rova-T, represents a multi-billion dollar peak revenue opportunity, with commercialization expected in 2018

Expands AbbVie’s oncology pipeline with four additional early stage clinical candidates

Broadens AbbVie’s oncology discovery capabilities with significant portfolio of pre-clinical assets

Allows AbbVie to expand and accelerate oncology presence

Complementary with AbbVie’s growing position in hematologic oncology and existing pipeline of solid tumor assets
Stemcentrx: Overview

About Stemcentrx

- Privately held company, founded in 2008 in South San Francisco, CA
- Fully integrated company with ~200 employees
  - >125 employees in target/biomarker discovery and validation
- Latest round of financing was raised at a $5BN valuation; investors include prominent private and public investors

Targeting Cancer Stem Cells

Cancer stem cells initiate and perpetuate tumor growth and are more resistant to chemotherapy and radiation therapies

Stemcentrx’s proprietary platforms identify cancer stem cells and discover novel biomarkers and targets

Stemcentrx engineers and manufactures antibodies and antibody drug conjugates
Complementary Strengths Accelerate Vision to Become a Leading Oncology Company

- Strong pre-clinical discovery and development capabilities in oncology, including small molecules and biologics
- Expertise in medicinal chemistry and protein engineering
- Emerging strength in antibody drug conjugate (ADC) technology and development, with five ADCs currently in clinical development
- Expanding portfolio in solid tumors
- Growing position in hematological malignancies with on-market products Imbruvica and Venclexta, as well as several pipeline assets
- Expertise in discovery, development, regulatory and medical affairs
- Global R&D infrastructure and clinical trial network

- Proven discovery and development capabilities
- Lead asset, Rova-T, currently in late-stage development for small cell lung cancer (SCLC), represents multi-billion dollar peak opportunity
- Proprietary stem cell target identification and validation technology and expertise
- First three clinical stage drugs are all novel targets with single-agent activity in early phase trials (SCLC, TNBC, ovarian cancer)
- Productive, biology-driven discovery engine
- Strength in ADC technology
- SF Bay-area location augments AbbVie’s West Coast presence
Stemcentrx Lead Asset: Rova-T

A Novel and Promising Late-Stage Asset

- Targeted antibody drug conjugate (ADC) directed to a novel cancer antigen, DLL3, expressed in numerous solid tumor types
- Discovered using cancer stem cell biology
- DLL3 is expressed on cancer stem cells and other tumor cells (not expressed in normal tissue)
- Rova-T is uniquely positioned to target both tumor cells and cancer stem cells
- Lead indication for Rova-T is SCLC; DLL3 is expressed in >80% of SCLCs
- In Phase I/II studies in relapsed SCLC, Rova-T has demonstrated promising results: ORR 44% and CBR 78% in DLL3+ patients; response rate similar in second- and third-line
  - Registrational trials for third-line SCLC underway; expect commercialization in 2018
  - Recently filed for FDA Breakthrough Designation
- Strong potential to move to earlier lines within the SCLC treatment paradigm
  - Studies designed to select regimen for first-line registration program will begin in 2Q16
- Expression of DLL3 suggests Rova-T may be useful across multiple tumor types, including metastatic melanoma, glioblastoma multiforme and some prostate, pancreatic and colorectal cancers

Small Cell Lung Cancer Opportunity

- Aggressive, difficult-to-treat form of cancer which accounts for roughly 15% of all lung cancers
- More than 60,000 diagnosed annually (US, EU5 and Japan)\(^1\)
- Limited treatment options: landscape has not changed in >30 years
  - Only one currently approved treatment for relapsed SCLC
  - No approved agents for third-line SCLC
- Significant unmet need: Five year survival rate for SCLC is only ~6%

Source (1) 2015 data, CancerMpact
Compelling Phase I/II Data in SCLC

- Rova-T is the first biomarker targeted therapy to show significant benefit in SCLC
- ORR 44% and CBR 78% in DLL3+ patients; response rate similar in 2nd and 3rd line
- Manageable safety profile
- Updated data, including compelling overall survival data, to be disclosed during oral presentation at upcoming ASCO meeting; selected as “Best of ASCO 2016”

Source: ESMO 2015 Data
### Rova-T: Potential in Other Tumor Types

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>2015 US/EU5 Drug-Treated Patients</th>
<th>% of patients with DLL3 Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCLC</td>
<td>&gt;60,000</td>
<td>80%</td>
</tr>
<tr>
<td>Large Cell Neuroendocrine Carcinoma (LCNEC)</td>
<td>11,100</td>
<td>70%</td>
</tr>
<tr>
<td>Metastatic Melanoma</td>
<td>30,000</td>
<td>50%</td>
</tr>
<tr>
<td>Glioblastoma Multiforme (GBM)</td>
<td>31,500</td>
<td>58%</td>
</tr>
<tr>
<td>Pancreatic (NEC)</td>
<td>4,175</td>
<td>70%</td>
</tr>
<tr>
<td>Other NEC (prostate, colorectal, etc.)</td>
<td>29,500</td>
<td>70%</td>
</tr>
</tbody>
</table>
Rova-T Represents a Significant Opportunity

Rova-T: A Compelling Growth Platform

Potential for Up to $5BN in Peak-Year Revenues

- Data supports high probability of success in relapsed SCLC
- High likelihood for use in first-line SCLC
- Potential in other solid tumors where DLL3 is expressed
Rova-T Clinical Program Synopsis

**Third-Line Small Cell Lung Cancer**
- Compelling Phase I/II data in 3L SCLC presented at ESMO 2015; additional updated longer-term data, including OS, to be presented at ASCO 2016
- Confirmatory third-line registration trial (TRINITY) currently underway
- Expect to complete enrollment by the end of 2016

**First-Line Small Cell Lung Cancer**
- Advancing rapidly into first-line SCLC
- On the cusp of initiating study designed to select optimal regimen for registrational program
- Four-arm trial will evaluate several permutations of Rova-T and standard-of-care chemotherapy, including both monotherapy and combination arms
- Expect to begin first-line SCLC registrational trial 1H17

**Additional Trials**
- Advancing eight-arm Phase I/II “basket study” evaluating Rova-T as monotherapy in patients with a range of tumors, including: metastatic melanoma, medullary thyroid cancer, glioblastoma, large cell neuroendocrine carcinoma, neuroendocrine prostate, high grade gastroenteropancreatic neuroendocrine carcinoma, other neuroendocrine carcinoma and other solid tumors
- Study posted on clinicaltrials.gov, on track to start enrolling patients 2Q16
- Additional first-line studies planned, including a Phase I study to assess the safety of Rova-T in combination with antibody therapy targeting the PD-1/PD-L1 axis, on track to be initiated during 2H16

Robust Development Plan Enhanced by AbbVie’s Global R&D Infrastructure
### Stemcentrx: Additional Detail

#### Rova-T

- Provides anchor asset for solid tumors with multi-billion dollar peak revenue potential
- Targeted antibody drug conjugate
- Registrational trials for third-line SCLC underway; targeting commercialization in 2018
- High likelihood of moving to earlier lines in the SCLC treatment paradigm
- Potential for Rova-T in other solid tumors

#### Pipeline

- Broadens oncology pipeline with four additional novel early stage candidates
- Stemcentrx pipeline includes four additional clinical candidates being evaluated in trials across a range of solid tumors
- Two additional ADCs in Phase IA trials in SCLC and ovarian cancer
- Two partnered Phase IB assets; ability to opt-in on one
- Two additional INDs for new targets in 2016
- The potential for three or more additional INDs in 2017

#### Discovery Engine

- Enhances oncology discovery capabilities via productive engine utilizing cancer stem cell biology-driven approach
- Significant portfolio of pre-clinical assets
- Technology platform has strong potential for continued asset generation to drive discovery and development in solid tumors
- Core technology utilizes a large (>700) proprietary library of patient-derived tumor xenograft (PDX) animal models and leverages stem cell biology to identify and validate therapeutic targets
## Strengthening our Position in Oncology

### Hematologic Oncology

**Imbruvica**
- First-in-class BTK-inhibitor; five approved indications, including recent approval for first-line CLL
- Broad development program ongoing, including studies in: DLBCL; FL; MCL; MZL; Multiple Myeloma; AML; Graft Vs. Host; Pancreatic Cancer; Solid Tumors (combo with PDL-1)
- Peak-year sales to AbbVie: >$7BN

**Venclexta**
- Recently FDA approved for first indication: R/R CLL (17P del)
- Broad development program underway; evaluating in a variety of blood cancers
- Received Breakthrough Designations for R/R CLL in combo with Rituxan and for AML in combo with hypomethylating agents

**Empliciti**
- Partnered asset with BMY; approved for R/R multiple myeloma, expect first-line MM data 2H16

**Duvelisib**
- Dual PI3 kinase inhibitor in development in partnership with Infinity; data in relapsed/refractory NHL and CLL 2H16

### Solid Tumors

**Rova-T**
- Compelling anchor asset for treatment of solid tumors
- DLL3-targeted ADC with compelling Phase I/II data in relapsed SCLC
- Registral trials in relapsed SCLC ongoing, targeting commercialization in 2018
- Initiating registrational studies in first-line SCLC in 1H2017
- Evaluating in multiple tumor types
- Multi-billion dollar peak revenue potential

**Veliparib**
- Late-stage PARP-inhibitor being studied in a range of solid tumors
- Five Phase III studies underway in lung, breast and ovarian cancer
- Differentiated strategy relative to other PARPs in development
- Registration data beginning in 2017

**ABT-414**
- Leveraging strength in protein engineering to develop ADC for glioblastoma multiforme (GBM)
- Large randomized comparative registrational trials are ongoing in first- and second-line GBM

### Early Stage Programs

**Early Stage Programs**
- Portfolio of promising ADCs and other novel approaches in early development
- Expect several immuno-oncology assets to move into clinic 2H16
- Stemcentrx pipeline of four additional novel clinical assets and portfolio of pre-clinical assets augment our early-stage efforts
### Pipeline Assets Span Attractive Specialty Categories

<table>
<thead>
<tr>
<th>Phase I</th>
<th>Phase II</th>
<th>Registral/Phase III</th>
<th>Submitted</th>
<th>Recent Approvals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rova-T:</strong> Neuroendocrine Tumors</td>
<td><strong>ABT-199:</strong> AML</td>
<td><strong>Rova-T:</strong> SCLC</td>
<td><strong>Imbruvica:</strong> CLL (Relapsed/Refractory)</td>
<td><strong>Humira:</strong> Uveitis</td>
</tr>
<tr>
<td><strong>SC002:</strong> Solid Tumors</td>
<td><strong>ABT-199:</strong> inHL/DLBCL</td>
<td></td>
<td><strong>Imbruvica:</strong> CLL (R/R combo with B/R)</td>
<td><strong>Humira:</strong> New Pen Device</td>
</tr>
<tr>
<td><strong>SC003:</strong> Solid Tumors</td>
<td><strong>ABT-199:</strong> Multiple Myeloma</td>
<td></td>
<td><strong>Imbruvica:</strong> Pancreatic Cancer</td>
<td><strong>Vieka 3QD:</strong> HCV (U.S. and EU)</td>
</tr>
<tr>
<td><strong>PTK7</strong>: Solid Tumors</td>
<td><strong>Duvelisib:</strong> iNHL (R/R)</td>
<td></td>
<td></td>
<td><strong>Imbruvica:</strong> CLL (TN, 65+ U.S.)</td>
</tr>
<tr>
<td><strong>EFN4A</strong>: Solid Tumors</td>
<td><strong>Imbruvica:</strong> Multiple Myeloma</td>
<td></td>
<td></td>
<td><strong>Vieka-Pak:</strong> HCV</td>
</tr>
<tr>
<td><strong>ABBV-838:</strong> Multiple Myeloma</td>
<td><strong>Imbruvica:</strong> AML</td>
<td></td>
<td></td>
<td><strong>Imbruvica:</strong> RBV-Free GT1b cirrhotic</td>
</tr>
<tr>
<td><strong>ABBV-399:</strong> Solid Tumors</td>
<td><strong>Imbruvica:</strong> FL (TN)</td>
<td></td>
<td></td>
<td><strong>Technivie:</strong> HCV (GT4)</td>
</tr>
<tr>
<td><strong>ABT-165:</strong> Solid Tumors</td>
<td><strong>Imbruvica:</strong> MZL (R/R)</td>
<td></td>
<td></td>
<td>2-DAA Japan: HCV (GT1b)</td>
</tr>
<tr>
<td><strong>ABT-RTA 408:</strong> Solid Tumors</td>
<td><strong>Imbruvica:</strong> Graft V Host</td>
<td></td>
<td></td>
<td><strong>Veliparib:</strong> NSCLC (Squamous)</td>
</tr>
<tr>
<td><strong>ABBV-075:</strong> Solid Tumors and Hem Onc</td>
<td><strong>BI 655066:</strong> Crohn’s Disease</td>
<td></td>
<td></td>
<td><strong>Veliparib:</strong> NSCLC (Non-squamous)</td>
</tr>
<tr>
<td><strong>ABBV-085:</strong> Solid Tumors</td>
<td><strong>BI 655066:</strong> PsA</td>
<td></td>
<td></td>
<td><strong>Veliparib:</strong> Breast Cancer (Neo)</td>
</tr>
<tr>
<td><strong>ABBV-221:</strong> Solid Tumors</td>
<td><strong>BI 655066:</strong> Asthma</td>
<td></td>
<td></td>
<td><strong>Veliparib:</strong> Breast Cancer (BRCA)</td>
</tr>
<tr>
<td><strong>Imbruvica:</strong> Solid Tumors</td>
<td><strong>ABT-122:</strong> RA</td>
<td></td>
<td></td>
<td><strong>Veliparib:</strong> Ovarian Cancer</td>
</tr>
<tr>
<td><strong>ABI-494:</strong> Crohn’s Disease</td>
<td><strong>ABI-122:</strong> PsA</td>
<td></td>
<td></td>
<td><strong>ABT-414:</strong> GBM</td>
</tr>
<tr>
<td><strong>ABI-981:</strong> Osteoarthritis</td>
<td><strong>ABT-494:</strong> RA</td>
<td></td>
<td></td>
<td><strong>ABI-494:</strong> GBM</td>
</tr>
<tr>
<td><strong>ALX-0061:</strong> RA</td>
<td><strong>BI 655066:</strong> Psoriasis</td>
<td></td>
<td></td>
<td><strong>ABI-494:</strong> GBM</td>
</tr>
<tr>
<td><strong>ABI-RTA 408:</strong> FA &amp; MM</td>
<td><strong>ABI-493/ABI-530:</strong> HCV</td>
<td></td>
<td></td>
<td><strong>ABI-493/ABI-530:</strong> HCV</td>
</tr>
<tr>
<td><strong>AbbVie-974:</strong> Cystic Fibrosis</td>
<td><strong>Elagolix:</strong> Endometriosis</td>
<td></td>
<td></td>
<td><strong>AbbVie-974:</strong> Cystic Fibrosis</td>
</tr>
<tr>
<td><strong>AbbVie-2222:</strong> Cystic Fibrosis</td>
<td><strong>Elagolix:</strong> Uterine Fibroids</td>
<td></td>
<td></td>
<td><strong>AbbVie-2222:</strong> Cystic Fibrosis</td>
</tr>
<tr>
<td><strong>AbbVie-399:</strong> Solid Tumors</td>
<td><strong>Atrasentan:</strong> Diabetic Nephropathy</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Transaction Details

• AbbVie will acquire Stemcentrx for an upfront transaction value of $5.8BN
  ➢ Deal structure includes contingent component: Success-based milestone payments for the achievement of certain clinical and regulatory developments
    — First-line SCLC U.S. approval, including NCCN Guidelines Recommendation ($2BN)
    — Commencement of registrational trials for four additional assets, each requiring >$1BN in revenue ($500MM each)

• AbbVie expects to fund the transaction through a combination of new debt and stock
  ➢ Stemcentrx holders opted for stock component to retain ownership stake in the asset and tax considerations
  ➢ Post-close accelerated share repurchase program for 100% of equity component planned in 2016

• Approved by both companies’ Board of Directors

• Closing expected in 2Q16 subject to regulatory approvals and other customary closing conditions

• AbbVie expects this transaction to be approximately $0.20 dilutive to our ongoing EPS in 2016, reflecting a half year expense related to R&D investment and operating and interest expense
  ➢ AbbVie is updating 2016 adjusted diluted earnings per share guidance to $4.62 to $4.82, reflecting growth of 10 percent at the mid-point
  ➢ First indication launch in 2018, positive operating margin in 2019, EPS accretive beginning in 2020
Summary

• Positions AbbVie to become a **leading oncology company**
  ➢ Provides AbbVie with a **attractive platform for solid tumors**
  ➢ Highly complementary with our growing hematologic oncology franchise and existing portfolio of solid tumor assets

• Anchor asset, **Rova-T, represents a multi-billion dollar peak revenue opportunity**
  ➢ Registrational trials for 3L SCLC underway; targeting commercialization of first indication in 2018

• **Broadens AbbVie’s early-stage oncology pipeline**, with four additional early-stage clinical candidates, targeting novel oncology antigens
  ➢ Pipeline also includes two compounds expected to have INDs filed in 2016, as well as several additional ADCs with preclinical validation

• **Enhances AbbVie’s oncology discovery capabilities** via a productive discovery engine utilizing a novel, cancer stem cell approach
  ➢ Technology platform has strong potential for continued asset generation to drive discovery and development in solid tumors

• **Adds to AbbVie’s long-term growth** prospects, providing another compelling growth platform
  ➢ Further diversifies AbbVie’s revenue base beginning in 2018 and will enhance our EPS growth in 2020 and beyond